arrow
Á

Ángel Ramírez-Fernández

Perelman School of Medicine
H指数:7
被引数:449

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection

模块化 γ δ tcr-t平台,将KRAS pMHC靶向与可重复剂量的mRNA接合器重定向相结合

2026-07-300
OA
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer

泛血液学癌症对嵌合抗原受体 (CAR) T细胞治疗反应的预测生物标志物

2026-03-090
PRE
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy

CD4 T细胞介导BCMA car-t细胞治疗后car-t细胞相关的免疫相关不良事件

2026-01-150
PRE
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy

CCR5靶向的异基因γ-δ CD19嵌合抗原受体T细胞用于HIV相关B细胞恶性免疫治疗

2025-10-210
PRE
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

分泌CD19 T细胞结合剂的CD22 CAR-T细胞,用于改善B细胞急性淋巴细胞白血病进展的控制

2025-04-300
OA
CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts
2024-08-271
OA
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

分泌抗BCMA T细胞衔接剂的工程化T细胞控制多发性骨髓瘤并促进体内免疫记忆

2024-02-145
PRE
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
2023-04-2410
OA
IL-6-based mortality risk model for hospitalized patients with COVID-19
2020-10-01146
OAAI